DECEMBER 12, 2022 – ANNOUNCEMENT NO. 13

Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.

Please see attachment.

CONTACT INFORMATION

Novozymes: Investor Relations Tobias Cornelius Björklund +45 3077 8682 tobb@novozymes.com	Chr. Hansen: Investor Relations Anders Mohr Christensen +45 2515 2364 dkamc@chr-hansen.com
Press Relations Lina Danstrup +45 3077 0552 lind@novozymes.com	Press Relations Sanne Seyer-Hansen +45 6038 6207 dksash@chr-hansen.com

Attachment

• No. 13 Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner